U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H20N4O6
Molecular Weight 376.3639
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIBOFLAVIN

SMILES

CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=N2

InChI

InChIKey=AUNGANRZJHBGPY-SCRDCRAPSA-N
InChI=1S/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s1

HIDE SMILES / InChI

Molecular Formula C17H20N4O6
Molecular Weight 376.3639
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22406738

Riboflavin (vitamin B2) is part of the vitamin B group. Riboflavin 5’-phosphate is the precursor of two coenzymes, flavin adenine dinucleotide and flavin mononucleotide, which catalyze oxidation/reduction reactions involved in a number of metabolic pathways. FAD and riboflavin phosphate in foods are hydrolyzed in the intestinal lumen by nucleotide diphosphatase and a variety of nonspecific phosphatases to yield free riboflavin, which is absorbed in the upper small intestines by a sodium-dependent saturable mechanism. Riboflavin has been used in several clinical and therapeutic situations. For over 30 years, riboflavin supplements have been used as part of the phototherapy treatment of neonatal jaundice. Corneal ectasia is a progressive thinning of the cornea; the most common form of this condition is keratoconus. Collagen cross-linking is a non-surgical treatment intended to slow progression of corneal ectasia by strengthening corneal tissue. The standard protocol calls for application directly to the eye of a 0.1% riboflavin solution for 30 minutes followed by 30 minutes of ultraviolet-A irradiation with a wavelength of 370 nm and power of 3 mW/cm2. Under the conditions used for corneal collagen cross-linking, riboflavin 5‘-phosphate functions as a photo enhancer and generates singlet oxygen which is responsible for the cross-linking.

Originator

Sources: Journal of Biological Chemistry (1928), 79, 733-8.iez8K9UZvDozY4ZRMmHj4&hl=ru&sa=X&ved=0ahUKEwiJ1reL0b_PAhWJVBQKHbdGBvEQ6AEIQjAF#v=onepage&q=Vitamin%20B2%20was%20discovered%20in%201920s&f=false
Curator's Comment: https://books.google.ru/books?id=b9ahvNjPFO8C&pg=PA63&lpg=PA63&dq=Vitamin+B2+was+discovered+in+1920s&source=bl&ots=KeZDSvz8CS&sig=gvCH_-

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PHOTREXA

Approved Use

PHOTREXA® VISCOUS and PHOTREXA® are indicated for use in corneal collagen cross-linking in combination with the KXL™ System for the treatment of 1.1 Progressive keratoconus 1.2 Corneal ectasia following refractive surgery.

Launch Date

2016
Primary
PHOTREXA

Approved Use

PHOTREXA® VISCOUS and PHOTREXA® are indicated for use in corneal collagen cross-linking in combination with the KXL™ System for the treatment of 1.1 Progressive keratoconus 1.2 Corneal ectasia following refractive surgery.

Launch Date

2016
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
217.72 nM
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIBOFLAVIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
674.2 nM × h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIBOFLAVIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
66 min
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIBOFLAVIN unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Riboflavin carrier protein: a serum and tissue marker for breast carcinoma.
2001-09-20
Helix stabilization in the C-terminal peptide of chicken riboflavin carrier protein enhances immunogenicity and prolongs contraceptive potential as an epitope-based vaccine in female rats.
2001-09-14
Biosynthesis of the phosphodiester bond in coenzyme F(420) in the methanoarchaea.
2001-09-11
The pH-dependent role of superoxide in riboflavin-catalyzed photooxidation of 8-oxo-7,8-dihydroguanosine.
2001-09-06
Validity and reproducibility of a food frequency questionnaire for pregnant Finnish women.
2001-09-01
Mechanism of the fluorescent light induced suppression of Curly phenotype in Drosophila melanogaster.
2001-09
Nutritional assessment in various stages of liver cirrhosis.
2001-09
Crystallization and preliminary crystallographic analysis of the recombinant N-terminal domain of riboflavin synthase.
2001-09
Nutritional status and dietary intakes of children aged 2-5 years and their caregivers in a rural South African community.
2001-09
Metabolic flux analysis with a comprehensive isotopomer model in Bacillus subtilis.
2001-09
Stoichiometric growth model for riboflavin-producing Bacillus subtilis.
2001-09
A Plackett-Burnam screening design directs the efficient formulation of multicomponent DRV liposomes.
2001-09
The effects of thyroxine isomers on free-radical oxidation processes in subcellular fractions of rat cerebral cortex.
2001-08-18
Photosensitizer initiated attacks on DNA under dry conditions and their inhibition: a DNA archiving issue.
2001-08-15
Flavin specificity and subunit interaction of Vibrio fischeri general NAD(P)H-flavin oxidoreductase FRG/FRase I.
2001-08-01
Reagentless chemiluminescence flow sensor for the determination of riboflavin in pharmaceutical preparations and human urine.
2001-08
Domain structure of riboflavin synthase.
2001-08
Effect of photosensitizer riboflavin on the fate of 2,4,6-trinitrotoluene in a freshwater environment.
2001-08
[Dietary and biochemical riboflavin status in a cohort of young people in the community of Madrid].
2001-07-31
Synergistic interactions of multiple mutations on catalysis during the hydroxylation reaction of p-hydroxybenzoate hydroxylase: studies of the Lys297Met, Asn300Asp, and Tyr385Phe mutants reconstituted with 8-Cl-flavin.
2001-07-31
Riboflavin treatment of antiretroviral induced lactic acidosis and hepatic steatosis.
2001-07
Spatially focused deposition of capillary electrophoresis effluent onto surface-enhanced Raman-active substrates for off-column spectroscopy.
2001-07
Alternative therapies in headache. Is there a role?
2001-07
Structures of coenzyme F(420) in Mycobacterium species.
2001-07
Thiamine, riboflavin, pyridoxine, and vitamin C status in premature infants receiving parenteral and enteral nutrition.
2001-07
Nutritional composition of uncommon foods and their role in meeting micronutrient needs.
2001-07
Long-term nutrient intake and early age-related nuclear lens opacities.
2001-07
Use of vitamin supplements and cataract: the Blue Mountains Eye Study.
2001-07
Riboflavin uptake in human trophoblast-derived BeWo cell monolayers: cellular translocation and regulatory mechanisms.
2001-07
B vitamins induce an antinociceptive effect in the acetic acid and formaldehyde models of nociception in mice.
2001-06-15
The solution structure of the N-terminal domain of riboflavin synthase.
2001-06-15
Riboflavin synthesis genes ribE, ribB, ribH, ribA reside in the lux operon of Photobacterium leiognathi.
2001-06-15
Light-dependent generation of reactive oxygen species in cell culture media.
2001-06-15
Efficient pyruvate production by a multi-vitamin auxotroph of Torulopsis glabrata: key role and optimization of vitamin levels.
2001-06
Vitamin B intake and status in healthy Havanan men, 2 years after the Cuban neuropathy epidemic.
2001-06
Considerations in planning vegan diets: children.
2001-06
Effect of UV irradiation on type I collagen fibril formation in neutral collagen solutions.
2001-06
[Energy and nutrient intake in compulsory high school students].
2001-06
Diet quality, nutrient intake, weight status, and feeding environments of girls meeting or exceeding recommendations for total dietary fat of the American Academy of Pediatrics.
2001-06
Frontal gel chromatographic analysis of the interaction of a protein with self-associating ligands: aberrant saturation in the binding of flavins to bovine serum albumin.
2001-06
[Effect of coenzyme Q10 in patients with kidney diseases].
2001-05-24
Antioxidant activity of brahma rasayana.
2001-05
Children's nutrient intake at preschool and at home.
2001-05
Relationships between dietary intake and cognitive function level in Korean elderly people.
2001-03
Allergic sensitization and diet: ecological analysis in selected European cities.
2001-03
Selenium status in an iodine deficient population of the West Ivory Coast.
2001-03
In vivo expression of the collagen-related heat shock protein HSP47, following hyperthermia or photodynamic therapy.
2001
An improved photochemical method for the rapid spectrophotometric detection of superoxide dismutase.
2001
Effect of saturated fatty acid consumption on energy and nutrient intake and blood lipid levels in preschool children.
2001
Extracting biological information from DNA arrays: an unexpected link between arginine and methionine metabolism in Bacillus subtilis.
2001
Patents

Sample Use Guides

instill 1 drop topically on the eye every 2 minutes for 30 minutes. After 30 minutes, examine the eye under slit lamp for presence of a yellow flare in the anterior chamber. If flare is not detected, instill 1 drop every 2 minutes for an additional 2 to 3 drops and recheck for yellow flare. Once flare is observed, perform ultrasound pachymetry. If corneal thickness is less than 400 microns, instill 2 drops every 5 to 10 seconds until the corneal thickness increases to at least 400 microns.
Route of Administration: Other
Corneal stromal cells were covered with collagen (200 µL or 500 µL) and 0.1% riboflavin, and then exposed to ultraviolet light at 370 nm for 30 minutes
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:46:53 GMT 2025
Edited
by admin
on Mon Mar 31 17:46:53 GMT 2025
Record UNII
TLM2976OFR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LACTOFLAVIN
INCI  
INCI  
Preferred Name English
RIBOFLAVIN
DASH   EP   FCC   HSDB   II   INCI   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INCI   INN  
Official Name English
LACTO-FLAVIN
Common Name English
Riboflavine
Common Name English
RIBOFLAVIN [ORANGE BOOK]
Common Name English
RIBOFLAVIN [II]
Common Name English
RIBOFLAVIN [MART.]
Common Name English
RIBOFLAVIN [WHO-IP]
Common Name English
RIBOFLAVIN [EP MONOGRAPH]
Common Name English
C.I. FOOD YELLOW 15
Common Name English
RIBOFLAVIN SODIUM PHOSPHATE IMPURITY D [EP IMPURITY]
Common Name English
NCI-0033298
Code English
RIBOFLAVIN [JAN]
Common Name English
VITAMIN B2 [GREEN BOOK]
Common Name English
7,8-DIMETHYL-10-(1'-D-RIBITYL)ISOALLOXAZINE
Common Name English
RIBOFLAVIN [MI]
Common Name English
VITAMIN B-2
Common Name English
INS NO.101(III)
Common Name English
VITAMIN B2 [VANDF]
Common Name English
VITAMIN B2 (AS RIBOFLAVIN)
Common Name English
BISULASE
Brand Name English
RIBOFLAVINUM [WHO-IP LATIN]
Common Name English
VITAMIN-B2
Common Name English
E-101(III)
Common Name English
RIBOFLAVIN [USP-RS]
Common Name English
VITAMIN B2
GREEN BOOK   VANDF  
Common Name English
RIBOFLAVIN [HSDB]
Common Name English
RIBOFLAVIN [FCC]
Common Name English
RIBOFLAVINUM
HPUS   WHO-IP LATIN  
Common Name English
INS NO. 101(I)
Code English
RUSSUPTERIDINE YELLOW III
Common Name English
RIBOFLAVIN [VANDF]
Common Name English
RIBOFLAVIN [USP MONOGRAPH]
Common Name English
NSC-33298
Code English
INS-101(III)
Common Name English
Riboflavin [WHO-DD]
Common Name English
riboflavin [INN]
Common Name English
RIBOFLAVINUM [HPUS]
Common Name English
C.I. 50900
Common Name English
Classification Tree Code System Code
WHO-VATC QA11HA04
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
LIVERTOX NBK548710
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
WHO-ATC A11HA04
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
JECFA EVALUATION INS-101(III)
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
LOINC 6695-1
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
DSLD 2543 (Number of products:6659)
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
LOINC 27099-1
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 27
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
LOINC 49038-3
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
NCI_THESAURUS C45812
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
FDA ORPHAN DRUG 352511
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
FDA ORPHAN DRUG 344911
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
LOINC 18374-9
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
LOINC 2924-9
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
DSLD 203 (Number of products:536)
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
CODEX ALIMENTARIUS (GSFA) INS-101(I)
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
FDA ORPHAN DRUG 468414
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
WHO-ATC S01XA26
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
CFR 21 CFR 184.1695
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
CODEX ALIMENTARIUS (GSFA) INS-101(III)
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
LOINC 73723-9
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
Code System Code Type Description
HSDB
817
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
PUBCHEM
493570
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
CHEBI
17015
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
JECFA EVALUATION
INS-101(I)
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
RIBOFLAVIN
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY Description: A yellow to orange-yellow, crystalline powder; odourless or almost odourless. Solubility: Very slightly soluble in water; practically insoluble in ethanol (~750 g/l) TS, ether R, and acetone R. Category: Vitamin. Storage: Riboflavin should be kept in a tightly closed container, protected from light. Additional information: Riboflavin has a bitter taste. Solutions of Riboflavin, especially in dilute solutions of alkalis, deterioraterapidly when exposed to light. Definition: Riboflavin contains not less than 98.0% and not more than 102.0% of C17H20N4O6, calculated with reference to the dried substance.
SMS_ID
100000089010
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
EPA CompTox
DTXSID8021777
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
NSC
33298
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
CHEBI
176838
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
FDA UNII
TLM2976OFR
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
NCI_THESAURUS
C808
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
RS_ITEM_NUM
1603006
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
WIKIPEDIA
Riboflavin
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
ECHA (EC/EINECS)
201-507-1
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
MESH
D012256
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
ChEMBL
CHEMBL1534
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
EVMPD
SUB10298MIG
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
INN
419
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
WIKIPEDIA
RIBOFLAVIN
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
DAILYMED
TLM2976OFR
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
MERCK INDEX
m9595
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY Merck Index
DRUG CENTRAL
2834
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
CAS
83-88-5
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
CHEBI
57986
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
RXCUI
9346
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB00140
Created by admin on Mon Mar 31 17:46:53 GMT 2025 , Edited by admin on Mon Mar 31 17:46:53 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Related Record Type Details
METABOLITE ACTIVE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
correction factors: for the calculation of content, multiply the peak areas of the following impurity by the corresponding correction factor: impurity C = 2.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
correction factors: for the calculation of content, multiply the peak areas of the following impurity by the corresponding correction factor: impurity B = 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
correction factors: for the calculation of content, multiply the peak areas of the following impurity by the corresponding correction factor: impurity A = 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
IMPURITY -> PARENT
correction factors: for the calculation of content, multiply the peak areas of the following impurity by the corresponding correction factor: impurity D = 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
Related Record Type Details
ACTIVE MOIETY